Insider Selling: Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Sells $31,667.22 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 9,022 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $3.51, for a total transaction of $31,667.22. Following the completion of the sale, the insider owned 81,385 shares in the company, valued at $285,661.35. This represents a 9.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $65,229.12.
• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.33, for a total transaction of $35,231.40.
• On Thursday, July 2nd, Financial Lp Hrt acquired 7,851 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.54 per share, with a total value of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Down 8.1%

Shares of NASDAQ SHPH opened at $3.28 on Friday. The company’s fifty day moving average is $5.15 and its 200-day moving average is $10.18. The stock has a market cap of $2.09 million, a price-to-earnings ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a twelve month low of $2.90 and a twelve month high of $55.90.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the third quarter valued at about $357,000. Ikarian Capital LLC bought a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth about $124,000. Boothbay Fund Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth about $37,000. Finally, Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at approximately $26,000. Institutional investors own 4.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on SHPH. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .